Ipsen, a global specialty-driven pharmaceutical company, has decided to open new commercial headquarters in Basking Ridge, N.J.

The move is an important step forward for Ipsen in the U.S., after the significant investment in its Mass.-based facility focused on R&D and technical operations (notably bioproduction) and the recently announced completion of its U.S. Leadership Team for commercial operations.

Relocation of the company’s headquarters is expected to create more than 100 new full-time jobs in New Jersey where the growing pharmaceutical and biopharmaceutical industries were key factors in Ipsen’s decision to establish U.S. headquarters in the state.

“For Ipsen, the U.S. is a new market in which we see significant opportunity. The move to New Jersey gives us access to the best talents of the biopharma industry, critical to Ipsen’s growth,” said Marc de Garidel, chairman and CEO of Ipsen.

Garidel added that the new headquarters “conveys our commitment to provide care to patient communities in the U.S., and will enable us to expand Ipsen’s capabilities and capacity in the U.S. marketplace for our specialty endocrine and neurology products.”